Engineered Escherichia coli Nissle 1917 targeted delivery of extracellular PD-L1-mFc fragment for treating inflammatory bowel disease.
10.1016/j.apsb.2025.08.002
- Author:
Yuhong WANG
1
;
Lin HU
2
;
Lei WANG
3
;
Chonghai ZHANG
2
;
Wenhao SHEN
2
;
Hongli YANG
1
;
Min LI
3
;
Xin ZHANG
4
;
Mengmeng XU
5
;
Muxing ZHANG
6
;
Kai YANG
1
;
Xiaopeng TIAN
4
Author Information
1. Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
2. State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China.
3. Institute of Biology and Medical Sciences, Soochow University, Suzhou 215123, China.
4. National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
5. Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
6. Department of Clinical Nutrition, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
- Publication Type:Journal Article
- Keywords:
Escherichia coli Nissle 1917;
Gut microbes;
Inflammatory bowel disease;
Outer membrane vesicles;
Programmed cell death ligand 1;
Protein delivery;
T cell;
Targeted local therapy
- From:
Acta Pharmaceutica Sinica B
2025;15(11):6019-6033
- CountryChina
- Language:English
-
Abstract:
Inflammatory bowel disease (IBD) is an autoimmune disorder involving complex immune regulation, where balancing localized and systemic immunosuppression is a key challenge. This study aimed to enhance the therapeutic efficacy by engineering the probiotic Escherichia coli Nissle 1917 (EcN). We removed endogenous plasmids pMUT1 and pMUT2 from wild-type EcN and expressed the mPD-L1 (19‒238 aa)-mFc fusion protein on the bacterial surface using a cytolysin A (ClyA) fragment. This modification stabilized mPD-L1 (19‒238 aa) protein expression and promoted its recruitment to outer membrane vesicles (OMVs). The engineered strain, EcNΔpMUT1/2-ClyA-mPD-L1-mFc (EcN-ePD-L1-mFc), features conditional ePD-L1-mFc expression under the araBAD promoter, enhancing gut-targeted release and reducing systemic side effects. This strain improved treatment targeting and efficiency by enabling direct ePD-L1-mFc interaction with immune cells at inflammation sites. OMVs from this strain induced Treg proliferation, inhibited effector T cell proliferation in vitro, and significantly improved intestinal inflammation and colonic epithelial barrier repair in vivo. Additionally, the bacterium restored intestinal microbiota balance, increasing Lactobacillaceae and reducing Bacteroides. This study highlights the engineered bacterium's potential for targeted intestinal immune modulation and offers a novel local IBD treatment approach with promising clinical prospects.
